I-Mab Announces Upcoming Participation at April Conferences
SHANGHAI, China and GAITHERSBURG, Md., March 31, 2021 (GLOBE NEWSWIRE) -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical...
Staff
Oncology Pharma Has Provided Initial Funding to NanoSmart Pharmaceuticals to Conduct Feasibility Studies for Initial Phases of IND-Enabling Activities
SAN FRANCISCO, CA, March 31, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) is pleased to...
Algernon Pharmaceuticals Announces Topline Data From its Phase 2b/3 COVID-19 Trial of Ifenprodil
VANCOUVER, British Columbia, March 31, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or...
Spectral Medical’s Wholly-Owned Subsidiary Dialco Medical Announces Receipt of Health Canada License for DIMI
Immediately enables DIMI to be used within Canadian hospitals, clinics and in homeTORONTO, March 31, 2021 (GLOBE NEWSWIRE) -- Spectral...
WW International Announces Proposed Private Offering of $500 Million of its Senior Secured Notes Due 2029
NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (the “Company”) announced today that it intends...
CELSION CORPORATION ANNOUNCES $15 MILLION REGISTERED DIRECT OFFERING
LAWRENCEVILLE, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered...
Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update
NORCROSS, Ga., March 31, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
Sienna Announces Renewal of Normal Course Issuer Bid
MARKHAM, Ontario, March 31, 2021 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna”) (TSX: SIA) announced today that the Toronto...
SmileDirectClub To Introduce Its Market-Leading Telehealth Solution To Mexico
Company Continues International Growth To Serve Untapped Market of Consumers Without Access to Affordable, Convenient Oral CareNASHVILLE, Tenn., March 31, 2021...
New Research Indicates ProFound AI May Reduce Interval Breast Cancer Rates
Retrospective analysis published in Journal of Medical Screening suggests that ProFound AI for 2D Mammography could have helped detect 48%...
Inovalon Data Powers New Insights on Diverse Healthcare Populations
Data-Driven Research Presented at Academy of Managed Care Pharmacy (AMCP), ISPOR Annual Meeting and Key Spring Conferences Powered by Inovalon’s...
Delcath Systems, Inc. Announces Fourth Quarter 2020 Results, Highlights Preliminary Positive FOCUS Trial Results; Conference Call Today at 8:00am Eastern Time
NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the...
Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates
- Successfully completed Initial Public Offering raising approximately US$161 million in gross proceeds--Reported clinical data for anti-CD137 and two anti-CTLA-4...
BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology
BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology BridgeBio, through...
Total number of shares and voting rights in Zealand Pharma at March 31, 2021
Company announcement – No. 18/ 2021 Total number of shares and voting rights in Zealand Pharma at March 31, 2021...
ProMIS Neurosciences Announces Fiscal Year 2020 Results
TORONTO and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the...
Wesana Health Announces Closing of C$16.1 Million Oversubscribed Private Placement
Appoints George Steinbrenner IV to its Board of DirectorsCHICAGO, March 31, 2021 (GLOBE NEWSWIRE) -- Wesana Health Inc. (“Wesana” or...
Delcath Systems, Inc. Announces Positive Preliminary Results from Phase 3 FOCUS Trial of HEPZATO in Patients with Metastatic Ocular Melanoma
Based on Preliminary Data, FOCUS Trial Achieves Prespecified Success Threshold Conference Call Today at 8:00am Eastern Time NEW YORK, March...
BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology
- BridgeBio, through its affiliate QED (“BridgeBio”), and Helsinn to co-commercialize infigratinib for oncology and all other indications other than...
Flexion Therapeutics Announces First Patient Treated in FX301 Phase 1b Trial for Management of Post-Operative Pain
FX301 is a locally administered NaV1.7 inhibitor (funapide) formulated for extended release in a proprietary thermosensitive hydrogelProof-of-concept trial will evaluate...